Galectin Therapeutics Inc. (GALT) financial statements (2020 and earlier)

Company profile

Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD
NORCROSS, GA 30071
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments478315262910
Cash and cash equivalents478315262910
Other undisclosed current assets1110110
Total current assets:489416263011
Noncurrent Assets
Property, plant and equipment     00
Intangible assets, net (including goodwill)   0000
Intangible assets, net (excluding goodwill)   0000
Other noncurrent assets000    
Total noncurrent assets:0000000
TOTAL ASSETS:489416263011
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2234123
Accounts payable2011011
Accrued liabilities 223112
Employee-related liabilities     11
Interest and dividends payable000000 
Other undisclosed current liabilities1    (1)(0)
Total current liabilities:3234122
Noncurrent Liabilities
Liabilities, other than long-term debt0      
Other liabilities0      
Total noncurrent liabilities:0      
Total liabilities:3234122
Stockholders' equity
Stockholders' equity attributable to parent, including:445(1)1018211
Preferred stock    111
Common stock0000000
Additional paid in capital260194173167158140103
Accumulated deficit(216)(196)(181)(164)(140)(119) 
Other undisclosed stockholders' equity attributable to parent1777  (102)
Other undisclosed stockholders' equity2222777
Total stockholders' equity:46711225288
TOTAL LIABILITIES AND EQUITY:489416263011

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses(13)(14)(16)(21)(20)(15)(12)
Operating loss:(13)(14)(16)(21)(20)(15)(12)
Nonoperating income (expense)0(0)000(0)0
Investment income, nonoperating0000000
Interest and debt expense(0)(0)(0)    
Loss from continuing operations before equity method investments, income taxes:(13)(14)(16)(21)(20)(16)(12)
Loss from equity method investments     (0) 
Net loss:(13)(14)(16)(21)(20)(16)(12)
Other undisclosed net income attributable to parent000  0 
Net loss attributable to parent:(13)(14)(16)(21)(20)(16)(12)
Preferred stock dividends and other adjustments(0)(1)(1)(1)(1)(1)(1)
Other undisclosed net loss available to common stockholders, basic(7)  (0)(0)(0)(9)
Net loss available to common stockholders, diluted:(20)(15)(17)(22)(21)(17)(22)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(13)(14)(16)(21)(20)(16)(12)
Comprehensive loss, net of tax, attributable to parent:(13)(14)(16)(21)(20)(16)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: